With Exposure to Drugs Or Toxins."'' We Report Kept Hounds Noted Fleeting

Total Page:16

File Type:pdf, Size:1020Kb

With Exposure to Drugs Or Toxins. Letters to the Editor 1123 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.54.12.1123 on 1 December 1991. Downloaded from and the neuropathological findings which to changes in posture. The blurring became Our patient stopped using lindane when Binswanger considered essential to a disease persistent after three months and then he the association of pseudotumour cerebri and which he called "encephalitis subcorticalis developed intermittent blurring in his left lindane was brought to his attention; this was chronica progressiva". These "reliable eye. Shortly after he noticed early morning coincidentally reinforced when a neighbour's criteria" were introduced to differentiate occipital headaches and tinnitus. He had used puppies convulsed and died after exposure to "encephalitis subcorticalis" from "arterio- benzene hexachloride at least twice a month a 20% solution. Despite discontinuation of sclerotic brain degeneration" (which also for about 30 years to rid his beagle hounds of the pesticide the patient's intracranial pres- affects the cortex), from the "general paralysis fleas and ticks. He said he used a 20% sure remained elevated (440 mm CSF) and of the insane" and from senile dementia, concentrate to make dip and spraying headaches continued 11 months later when a which he knew could also be accompanied by applications but wore a mask and appropriate lumbo-peritoneal shunt was inserted. white matter changes.2 protective clothing. He was well built but not Removal of the toxin should result in allevia- The similarities between Bennett's' and obese. His neurological examination yielded tion of increased intracranial pressure. Per- Binswanger's own criteria are obvious. normal results except for visual findings: his haps the lindane caused permanent or prolon- Nevertheless, several striking discrepancies best corrected visual acuity was 6/36 OD and ged alteration of the arachnoid villi. Alter- appear noteworthy. The white matter atro- 6/9 OS. He had a right relative afferent natively, lindane may be present in fat cells phy in Binswanger's patients was most pro- pupillary defect. Ocular motility and slit lamp for an extended period and have a long lasting nounced in the occipital and temporal lobes, examinations were normal. Intraocular pres- effect on CSF absorption. Whether the whereas radiological changes are most com- sures were 21 and 23 mm Hg respectively. patient's liver damage was caused by previous monly found in the frontal lobes. According Ophthalmoscopic examination showed dis- chronic alcohol consumption or exposure to to Binswanger, "encephalitis subcorticalis" tinct swollen optic discs with small cups, loss lindane is unclear. The relation with lindane slowly and relentlessly progressed to a state of the nerve fibre layer in the right eye, and a exposure may not be coincidental because of decerebration, whereas Bennett et al ex- small pseudodrusen in the left eye, typical of other pesticides have been linked to cluded patients with severe dementia. Bins- chronic papilloedema. Goldmann perimetry pseudotumour cerebri in the past.2 The use wanger assumed that arteriosclerosis was the showed visual field loss characteristic of of lindane should be discontinued when cause ofdisease and mentioned the invariable chronic papilloedema. patients have unexplained raised intracranial presence of cerebral arteriosclerosis (which MRI of the head was normal except for a pressure. was, however, very mild in the only case he few small periventricular white matter LISA VERDERBER described extensively). He did not describe lesions; venous sinus thrombosis was not PATRICK LAVIN or other evidence of RALPH WESLEY hypertension systemic seen. A spinal tap showed an opening pres- Departments ofNeurology and Ophthalmology, vascular disease. sure of 400 mm CSF with one monocyte per Vanderbilt University Medical Center, It has already been pointed out that the cu mm, protein 0-34 Gm/l, glucose 2 mmol/l, Nashville, TN 37212, USA. relationship between Binswanger's findings and no evidence of infection. Other Correspondence to: Dr Lavin, M.D., 2100 Pierce and the modem "Binswanger's disease" laboratory values were notable only for Ave., Nashville, TN 37212, USA. remains open to question.' Binswanger did elevated cholesterol and triglyceride concen- not present a full account of the histopath- trations and mildly abnormal results of liver ology in his cases. This was left to Alzheimer, function tests. Thyroid function tests were 1 Ireland B, Corbett JJ, Wallace B. The search of who first used the eponym "Binswanger's normal; rheumatoid factor and antinuclear causes ofidiopathic intracranial hypertension. disease",4 and to Nissl.' Inconsistencies in antibodies were negative. Toxic screens for Arch Neurol 1990;47:315-20. Binswanger's original description may sup- lead, mercury, and arsenic were negative. 2 Sanbom GE, Selhorst JB, Calabrese VP, et al. port the speculation that he eventually re- Management included Pseudotumour cerebri and insecticide intox- dietary advice (weight ication. Neurology 1979;29:1222-7. garded the differentiation of such vascular loss), diuretics, and prednisone, but he sub- 3 Pramanik AK, Hansen RC. Transcutaneous dementias as too difficult or too unrewarding.2 sequently had bilateral optic nerve sheath gamma benzene hexachloride absorption and HANS FORSTL fenestration because of progressive visual toxicity in infants and children. Arch Der- ROBERT HOWARD matol 1979;115:1224-5. RAYMOND LEVY field loss. Ten months after diagnosis his field 4 Lee B, Groth P. Scabies: transcutaneous poison- Section of Old Age Institute ofPsychiatry, defects were stable, but his visual acuity ing during treatment. Pediatrics 1979;59:643. London SE5 8AF, UK remained impaired. 5 Solomen LM, Fahrner L, West DP, et al. Lindane, a gamma isomer of hexachloro- Gamma benzene hexachloride toxicity. Arch 1 Bennett DA, Wilson RS, Gilley DW, Fox JH. Dernat 1977;113:353-7. Clinical diagnosis of Binswanger's disease. cyclohexane used as a pesticide and an 6 Danopoulos E, Melissinos K, Katsas G. Serious Neurol ectoparasiticide, is metabolised by the liver poisoning by hexachlorocyclohexene. Clinical J Neurosurg Psychiatry 1990;53: http://jnnp.bmj.com/ 961-5. and distributed and stored in depot fat and and laboratory observations on 5 cases. Arch 2 Binswanger 0. Die Abgrenzung der allgemeinen of Indust Hygien 1953;8:582-7. progressiven Paralyse, I-III. Berl Klin other lipophilic tissues. It is commonly pres- 7 Heuser M, Heuser H. Pseudotumour cerebri Wochenschr 1894;49:1103-5, 1137-9, 1180-6. cribed topically as a 1% solution for scabies following insecticide (lindane) intoxication. (Tranl. by H Forstd et al: Binswanger on but is available in concentrations of 0 5%- Acta Univ Carol Med. 1976;75:133-5. Binswanger's disease. Intern J Geriatr Psy- 99%; our patient used a 20% veterinary 8 Sufnol C, Tussell JM, Gelpi C, Rodriguez-Farre chiat 1991;6:529-35.) E. Convulsant effect of lindane and regional 3 Olszewski I. Subcortical arteriosclerotic ence- concentration for his dogs. Lindane is a brain concentration of GABA and dopamine. phalopathy: review of the literature on the so- powerful CNS stimulant known to cause Toxicology 1988;49:247-52. called Binswanger's disease and presentation headache, nausea, vomiting, diarrhoea, con- 9 St Omer V. Investigation into mechanisms res- of 2 cases. World Neurol 1962;3:359-75. ponsible for seizures induced by chlorinated 4 Alzheimer A. Die Seelenstrorungen auf vulsions, muscle spasms, respiratory failure hydrocarbon pesticides. J Neurochem 1971; on September 26, 2021 by guest. Protected copyright. arteriosklerotischer Grundlage. Allg Z Psy- with cyanosis, coma, and death.'5 "Optic 18:365-74. chiat 1902;59:695-701. (Transl: Mental dis- neuritis" after "improper use" of lindane turbances ofvascular origin.) Neuropsychiatry powder has also been reported.6 Heuser and Neuropsychol Behav Neurol (in print). 5 Nissl F. Zur Kasuistik der arteriosklerotischen Heuser briefly described "pseudotumour Demenz (ein Fall von sogenannter Ence- cerebri" in a farmer with localised brain phalitis subcorticalis). Z Ges Neurol Psychiat oedema, after "prolonged professional 1920;19:438-43. inhalation" oflindane;7 but the appearance of the optic discs and the spinal fluid pressure Motor neuron syndrome in the arms were not reported. The mechanism oflindane after radiation treatment toxicity is unknown, although it is highly Pseudotumour cerebri and chronic ben- lipid soluble and may act as a gamma-amino- Radiation myelopathy is a rare but well zene hexachloride (lindane) exposure butyric acid-A (GABA-A) receptor antagon- established complication of radiotherapy ist to produce convulsive effects and inter- leading to diagnostic difficulties with Pseudotumour cerebri, the syndrome of ference with the production and utilisation of neurological complications of the primary idiopathic intracranial hypertension and free ammonia in the brain.89 Chlordecone, a neoplasm, like epiduritis or spinal metas- papilloedema in the absence of a tumour or cyclodiene insecticide which also induces tasis.' We report a rare case of radiation obstructive hydrocephalus, may be associated seizures, has been implicated in causing myelopathy presenting as a cervical motor with exposure to drugs or toxins."'' We report pseudotumour cerebri by inhibition of ATP- neuron syndrome that developed three years a patient, repeatedly exposed to the pesticide ase activity, resulting in impaired resorption after local radiotherapy in which spinal cord benzene hexachloride (lindane), who de- of cerebrospinal fluid across the arachnoid magnetic resonance imaging (MRI) showed a veloped chronic intracranial hypertension. villi.' Lindane and chlordecone may have centrospinal cystic lesion. A 45 year old man (weighing 80 kg) who similar effects on the arachnoid villi as they A 44 year old man without relevant history kept hounds noted fleeting episodes of are both lipid soluble, neurotoxic chlorinated presented with dyspnoea and a rapidly grow- blurred vision in his right eye usually related hydrocarbons. ing cervical anterior mass. We found a mal-.
Recommended publications
  • Lindane Lotion USP, 1% RX Only WARNINGS
    Lindane Lotion USP, 1% RX Only WARNINGS: Lindane Lotion should only be used in patients who cannot tolerate or have failed first-line treatment with safer medications for the treatment of scabies. (See INDICATIONS AND USAGE.) Neurologic Toxicity Seizures and deaths have been reported following Lindane Lotion use with repeat or prolonged application, but also in rare cases following a single application used according to directions. Lindane lotion should be used with caution for infants, children, the elderly, and individuals with other skin conditions (e.g, atopic dermatitis, psoriasis) and in those who weigh < 110 lbs (50 kg) as they may be at risk of serious neurotoxicity. Contraindications Lindane Lotion is contraindicated in premature infants and individuals with known uncontrolled seizure disorders. Proper Use Instruct patients on the proper use of Lindane Lotion, the amount to apply, how long to leave it on, and avoiding re-treatment. Inform patients that itching occurs after the successful killing of scabies and is not necessarily an indication for re-treatment with Lindane Lotion. (See DOSAGE AND ADMINISTRATION.) DESCRIPTION Lindane Lotion USP, 1%, is an ectoparasiticide and ovicide. In addition to the active ingredient, lindane, it contains glycerol monostearate, cetyl alcohol, stearic acid, trolamine, carrageenan, 2- amino-2-methyl-1-propanol, methylparaben, butylparaben, perfume and water to form a lotion. Lindane is the gamma isomer of 1,2,3,4,5,6-hexachlorocyclohexane having the following structural formula: C6H6Cl6 M.W. 290.83 CLINICAL PHARMACOLOGY Lindane Lotion USP, 1%, is an ectoparasiticide and ovicide effective against Sarcoptes scabiei (scabies). Lindane exerts its parasiticidal action by being directly absorbed into the parasites and 1 their ova.
    [Show full text]
  • Revised Use-Function Classification (2007)
    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY IPCS INTOX Data Management System (INTOX DMS) Revised Use-Function Classification (2007) The Use-Function Classification is used in two places in the INTOX Data Management System: the Communication Record and the Agent/Product Record. The two records are linked: if there is an agent record for a Centre Agent that is the subject of a call, the appropriate Intended Use-Function can be selected automatically in the Communication Record. The Use-Function Classification is used when generating reports, both standard and customized, and for searching the case and agent databases. In particular, INTOX standard reports use the top level headings of the Intended Use-Functions that were selected for Centre Agents in the Communication Record (e.g. if an agent was classified as an Analgesic for Human Use in the Communication Record, it would be logged as a Pharmaceutical for Human Use in the report). The Use-Function classification is very important for ensuring harmonized data collection. In version 4.4 of the software, 5 new additions were made to the top levels of the classification provided with the system for the classification of organisms (items XIV to XVIII). This is a 'convenience' classification to facilitate searching of the Communications database. A taxonomic classification for organisms is provided within the INTOX DMS Agent Explorer. In May/June 2006 INTOX users were surveyed to find out whether they had made any changes to the Use-Function Classification. These changes were then discussed at the 4th and 5th Meetings of INTOX Users. Version 4.5 of the INTOX DMS includes the revised pesticides classification (shown in full below).
    [Show full text]
  • Antibiotics May Eradicate Gastrointestinal Immunodeficiency.8
    1122 Letters to the Editor J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.54.12.1122 on 1 December 1991. Downloaded from sitivity.? We present a case of OMM without pseudobulbar palsy. The association of vitro.8 Whipple's disease is associated with symptoms of Whipple's disease and with supranuclear gaze paresis with oculomas- immunodeficiency.8 Thus intestinal wall negative peroral jejunoileal biopsies, which ticatory myorhythmia, however, seems to be macrophages are ineffective in phagocytosing indicates the usefulness of laparotomy for pathognomonic of the effects of Whipple's intracellular gram positive bacilli, resulting in jejunoileal biopsies as an alternative to brain disease on the CNS.'2 This led us to perform inability to eliminate chronic infection.9 This biopsy to confirm Whipple's disease. surgical jejunal and mesenteric lymph node suggests that Whipple's disease may be con- A 47 year old woman was admitted in May biopsies rather than a brain biopsy despite sidered as a disease of macrophages.8 The 1988 in a depressed state. In June 1987 she negative endoscopic and numerous peroral periventricular and periaqueductal distribu- had noted progressive visual disturbance. distal jejunal and ileal biopsies. The nor- tion of the CNS involvement in Whipple's Rhythmic elevations of her right upper lip mality ofthe CT and MRI scans also suppor- disease consists of macrophagic infiltration appeared, and later, paroxysmal hypersomnia ted this decision. and subependymal nodules. Such a and considerable weight gain (10 kg). A nine The possibility of brain involvement with- "tumoural" involvement may explain why month course oftreatment for depression was out systemic manifestation in Whipple's dis- antibiotics with good BBB diffusion are not ineffective and her symptoms and signs ease should be kept in mind.
    [Show full text]
  • PASS Information
    H9X-MC-B010 Non-interventional PASS Final Study Report Page 1 PASS Information Title Utilisation of dulaglutide in European countries: A cross-sectional, multi-country and multi-source drug utilisation study using electronic health record databases Version identifier of the final study report Version 1.0 Date of last version of the final study report N/A EU PAS register number EUPAS13783 Active substance Dulaglutide (ATC code: A10BJ05) Medicinal product(s): Trulicity 0.75 mg solution for injection Trulicity 1.5 mg solution for injection Product reference: EU/1/14/956 Procedure number: EMEA/H/C/002825 Marketing authorisation holder(s) Eli Lilly Nederland B.V. Joint PASS No Research question and objectives The purpose of this study is to describe how dulaglutide is used among different patient groups in Europe. Primary objective: To describe the frequency of dulaglutide use in the population and characterise by age, gender, main comorbidities, and main co- prescriptions overall and in the following subgroups of interest: o Populations of interest: • Patients with severe renal failure • Patients with hepatic disease • Patients with heart failure • Patients with severe gastrointestinal disease • Children and adolescents (<18 years of age) • Elderly patients (≥75 years of age) • Pregnant or breast-feeding women o Medication use: • Medication errors • Off-label use Secondary objective: To describe the off-label use among each of the above populations of interest. Country(-ies) of study France, Germany, Spain, Sweden and the United Kingdom Author PPD Signature of principal investigator Signature on file/see approval date below Approval Date: 14-Nov-2019 GMT H9X-MC-B010 Non-interventional PASS Final Study Report Page 2 Marketing Authorisation Holder Marketing authorisation holder (MAH) Eli Lilly Nederland B.V.
    [Show full text]
  • A Saprolegnia Parasitica Challenge System for Rainbow Trout: Assessment of Pyceze As an Anti-Fungal Agent for Both Fish and Ova
    DISEASES OF AQUATIC ORGANISMS Published May 12 Dis Aquat Org l A Saprolegnia parasitica challenge system for rainbow trout: assessment of Pyceze as an anti-fungal agent for both fish and ova T. G.Pottinger*, J. G. Day NERC Institute of Freshwater Ecology, Windermere Laboratory, Far Sawrey, Ambleside, Cumbria, LA22 OLP, United Kingdom ABSTRACT: A reproducible Saprolegnia parasitica spore delivery system was developed and demon- strated to be effective in providing a sustained spore challenge for up to 10 d. Treatment of rainbow trout with slow-release intraperitoneal implants containing cortisol resulted in chronically elevated blood cortisol levels and rendered the fish susceptible to infection by S. parasitica when exposed to the spore challenge. Sham-implanted fish were not susceptible to infect~on.Bronopol (2-bromo-2-nitro- propane-1,3-dol), formulated as Pyceze, was effective in protecting predisposed fish from infection by S. parasitica when administered as a daily bathlflush treatment at concentrations of 15 mg I-' and greater. Pyceze was also demonstrated to protect fertilised rainbow trout ova from S. parasitica chal- lenge when administered as a daily bath/flush treatment at concentrations of between 30 and 100 mg 1-l. Pyceze appears to qualify as a safe and effective replacement for malachite green and formalin in the prevention of fungal infections in the aquaculture environment. KEY WORDS: Saprolegnia . Fungal infection . Salmonid . Bronopol - Pyceze . Cortisol INTRODUCTION chite green in combating mycotic infections of fish and fish eggs, but is safer for the operator, the fish, and Mycotic infections of farmed fish, primarily by water the environment. Among the alternative compounds moulds or pseudofungi of the genus Saprolegnia, rep- tested for antifungal activity are sodium chloride resent a significant economic and welfare problem.
    [Show full text]
  • A Single Amino Acid Substitution in the Third Transmembrane Region Has Opposite Impacts on the Selectivity of the Parasiticides
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/09/08/mol.117.109413.DC1 1521-0111/92/5/546–555$25.00 https://doi.org/10.1124/mol.117.109413 MOLECULAR PHARMACOLOGY Mol Pharmacol 92:546–555, November 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics A Single Amino Acid Substitution in the Third Transmembrane Region Has Opposite Impacts on the Selectivity of the Parasiticides Fluralaner and Ivermectin for Ligand-Gated Chloride Channels s Yunosuke Nakata, Toshinori Fuse, Kohei Yamato, Miho Asahi, Kunimitsu Nakahira, Fumiyo Ozoe, and Yoshihisa Ozoe Faculty of Life and Environmental Science, Shimane University, Matsue, Shimane, Japan (Y.N., T.F., K.Y, F.O., Y.O.); and Downloaded from Biological Research Laboratories, Nissan Chemical Industries, Ltd., Saitama, Japan (M.A., K.N.) Received May 16, 2017; accepted September 9, 2017 ABSTRACT Fluralaner (Bravecto) is a recently marketed isoxazoline ectopar- transmembrane region (TM3) with an aromatic amino acid molpharm.aspetjournals.org asiticide. This compound potently inhibits GABA-gated chloride dramatically enhanced the potency of fluralaner in the GluCls. channels (GABACls) and less potently glutamate-gated chloride In stark contrast to the enhancement of fluralaner potency, this channels (GluCls) in insects. The mechanism underlying this mutation eliminated the activation of currents and the potenti- selectivity is unknown. Therefore, we sought to identify the ation but not the antagonism of glutamate responses that are amino acid residues causing the low potency of fluralaner toward otherwise all elicited by the macrolide parasiticide ivermectin GluCls. We examined the fluralaner sensitivity of mutant housefly (IVM).
    [Show full text]
  • Study Protocol
    STUDY PROTOCOL FOR COMPASSIONATE AQUACULTURE INVESTIGATIONAL NEW ANIMAL DRUG (INAD) EXEMPTION FOR 35% PEROX-AID® (HYDROGEN PEROXIDE) FOR THE CONTROL OF ECTOPARASITES (INAD #11-669) Sponsor: U.S. Fish and Wildlife Service, Division of the National Fish Hatchery System ______________________ ___________________ Sponsor Signature Date Approved Manufacturer: Eka Chemicals Inc. 1775 West Oak Commons Court Marietta, Georgia 30062-2254 Facility for Coordination of 35% PEROX AID® INAD: Aquatic Animal Drug Approval Partnership Program 4050 Bridger Canyon Road Bozeman, Mt 59715 Proposed Starting Date: December 1, 2007 Proposed Ending Date: November 30, 2012 Study Director: Mr. Jim Bowker _________________________ ________________ Study Director Signature Date Clinical Field Trial Location and Trial Number: Facility ______________________________________________________________ Type or Print Name Investigator____________________________________________________________ Type or Print Name __________________________________________ ________________________ Investigator Signature Date 1 I. STUDY ID AND TITLE 3 II. SPONSOR 3 III. INVESTIGATORS/FACILITIES 4 IV. PROPOSED STARTING AND COMPLETION DATES: 4 V. BACKGROUND/PURPOSE 4 VI. SPECIFIC OBJECTIVES 6 VII. MATERIALS 7 VIII. EXPERIMENTAL UNIT 10 IX. ENTRANCE CRITERIA 10 X. TREATMENT GROUPS 11 XI. TREATMENT SCHEDULES 12 XII. TREATMENT RESPONSE PARAMETERS 15 XIII. FORMS FOR DATA COLLECTION 15 XIV. RECORD KEEPING PROCEDURES 16 XV. DISPOSITION OF INVESTIGATIONAL ANIMALS 16 XVI. DISPOSITION OF INVESTIGATIONAL
    [Show full text]
  • Laboratory and Field Studies to Investigate the Efficacy of a Novel
    Kryda et al. Parasites Vectors (2019) 12:445 https://doi.org/10.1186/s13071-019-3702-6 Parasites & Vectors RESEARCH Open Access Laboratory and feld studies to investigate the efcacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Diroflaria immitis) in dogs Kristina Kryda1*, Robert H. Six1, Kelly F. Walsh1, Susan J. Holzmer1, Sara Chapin1, Sean P. Mahabir1, Melanie Myers1, Tammy Inskeep1, Jady Rugg1, Blair Cundif1, Aleah Pullins1, Michael Ulrich2, John W. McCall3, Tom L. McTier1 and Steven J. Maeder1 Abstract Background: Diroflaria immitis is a flarial parasite of dogs that can cause serious or fatal cardiopulmonary disease. Three studies were conducted to evaluate the efcacy and safety of monthly treatment with moxidectin in a chew- able tablet product in combination with sarolaner and pyrantel to prevent heartworm disease in dogs after experi- mental challenge and in a clinical feld study in the USA. Methods: In two laboratory studies, dogs (8 per group) that had been inoculated 30 days prior with 50 third-stage D. immitis larvae were randomized to treatment on Day 0 with placebo or combination product, at the minimum dose of 24 µg/kg moxidectin, 2 mg/kg sarolaner and 5 mg/kg pyrantel (as pamoate salt). Study 2 also included groups treated with tablets containing moxidectin-alone (24 µg/kg) or sarolaner-alone (2 mg/kg). Efcacy was evaluated ~ 5 months after inoculation by adult heartworm counts at necropsy. In the feld study, 410 dogs 8 weeks-old from 23 USA veterinary clinics were treated for 11 months with either combination product at 24–48 µg/kg≥ moxidectin, 2–4 mg/kg sarolaner and 5–10 mg/kg pyrantel (n 272) or Heartgard® Plus (ivermectin/pyrantel) at the label recom- mended dose rate (n 138).
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug
    USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat.
    [Show full text]
  • Reflection Paper on Resistance in Ectoparasites
    1 13 September 2018 2 EMA/CVMP/EWP/310225/2014 3 Committee for Medicinal Products for Veterinary Use (CVMP) 4 Reflection paper on resistance in ectoparasites 5 Draft Draft agreed by Efficacy Working Party (EWP-V) May 2018 Adopted by CVMP for release for consultation September 2018 Start of public consultation 21 September 2018 End of consultation (deadline for comments) 31 August 2019 6 Comments should be provided using this template. The completed comments form should be sent to [email protected] 7 Keywords Ectoparasites, resistance to ectoparasiticides 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 8 Reflection paper on resistance in ectoparasites 9 Table of contents 10 1. Introduction ....................................................................................................................... 4 11 2. Definition of resistance ...................................................................................................... 4 12 3. Current state of ectoparasite resistance ............................................................................ 4 13 3.1. Ticks .............................................................................................................................. 4 14 3.2. Mites .............................................................................................................................
    [Show full text]
  • Known Bioactive Library: Microsource 1 - US Drug Collection
    Known Bioactive Library: Microsource 1 - US Drug Collection ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID antifungal, inhibits Penicillium 2091 A03 Microsource 00200046 GRISEOFULVIN 126-07-8 mitosis in metaphase griseofulvum 3505-38-2, 486-16-8 2091 A04 Microsource 01500161 CARBINOXAMINE MALEATE antihistaminic synthetic [carbinoxamine] 2091 A05 Microsource 00200331 SALSALATE analgesic synthetic 552-94-3 muscle relaxant 2091 A06 Microsource 01500162 CARISOPRODOL synthetic 78-44-4 (skeletal) antineoplastic, 2091 A07 Microsource 00210369 GALLIC ACID insect galls 149-91-7 astringent, antibacterial 66592-87-8, 50370-12- 2091 A08 Microsource 01500163 CEFADROXIL antibacterial semisynthetic 2 [anhydrous], 119922- 89-9 [hemihydrate] Rheum palmatum, 2091 A09 Microsource 00211468 DANTHRON cathartic 117-10-2 Xyris semifuscata 27164-46-1, 25953-19- 2091 A10 Microsource 01500164 CEFAZOLIN SODIUM antibacterial semisynthetic 9 [cefazolin] glucocorticoid, 2091 A11 Microsource 00300024 HYDROCORTISONE adrenal glands 50-23-7 antiinflammatory 64485-93-4, 63527-52- 2091 A12 Microsource 01500165 CEFOTAXIME SODIUM antibacterial semisynthetic 6 [cefotaxime] 2091 A13 Microsource 00300029 DESOXYCORTICOSTERONE ACETATE mineralocorticoid adrenocortex 56-47-3 58-71-9, 153-61-7 2091 A14 Microsource 01500166 CEPHALOTHIN SODIUM antibacterial semisynthetic [cephalothin] 2091 A15 Microsource 00300034 TESTOSTERONE PROPIONATE androgen, antineoplastic semisynthetic 57-85-2 24356-60-3, 21593-23- 2091 A16 Microsource 01500167 CEPHAPIRIN SODIUM
    [Show full text]